EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSAOCG00000007833
Gene Symbol: GABRG2
3 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSAOCG00000013857
Gene Symbol: GABRG3
4 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSAOCG00000014212
Gene Symbol: GABRG3
4 Cross references
223 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAOCG00000024113
Gene Symbol: GABBR1
4 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAOCG00000021480
Gene Symbol: GABBR1
3 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSAOCG00000018013
Gene Symbol: LOC111576347
3 Cross references
204 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSAOCG00000016196
Gene Symbol: LOC111581023
3 Cross references
193 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSAOCG00000019878
Gene Symbol: GLP2R
2 Cross references
204 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSAOCG00000016505
Gene Symbol: GCGR
1 Cross references
163 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSAOCG00000019197
Gene Symbol: LOC111565142
3 Cross references
207 Possible Orthologues:

Glucokinase

Ensembl ID : ENSAOCG00000006915
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSAOCG00000007977
Gene Symbol: GRIA2
3 Cross references
244 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).